<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627403</url>
  </required_header>
  <id_info>
    <org_study_id>HCI114354</org_study_id>
    <nct_id>NCT03627403</nct_id>
  </id_info>
  <brief_title>Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors</brief_title>
  <acronym>ESSENTIAL</acronym>
  <official_title>A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, prospective, single-arm study evaluating the efficacy and
      safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are
      refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">March 14, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, non-randomized, prospective, single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in spleen volume</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To assess the efficacy of selinexor on spleen volume reduction in subjects with myelofibrosis (PMF, PET-MF, or PPV-MF) refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Change and percentage change in spleen volume from baseline to EOT as measured by MRI or CT (in applicable patients).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events that Occur</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To assess the safety/tolerability and further characterize the safety profile of selinexor in PMF, PET-MF, or PPV-MF patients refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Secondary Endpoints: rate of adverse events (AEs) and serious adverse events (SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms score</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Proportion of patients with ≥ 50% reduction of total symptoms score as measured by the MPN-Symptoms Assessment Form (MPN-SAF) from baseline after 6 cycles of treatment.
The score will be reported as one mean score of all of the questions in the questionnaire. The higher the score, the worse the symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Overall response rate according to the 2013 IWG-MRT consensus criteria for treatment response in primary and secondary MF (post-PV and post-ET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Overall survival at 24 months from the initiation of study therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis</condition>
  <condition>Post-polycythemia Vera Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Selinexor, all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm Study, all patients will get selinexor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.</description>
    <arm_group_label>Selinexor, all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Diagnosis of primary myelofibrosis (PMF), post-essential thrombocytosis (PET-MF) or
             post-polycythemia vera (PPV-MF).

          -  Life expectancy ≥ 6 months.

          -  Prior treatment with ruxolitinib or any experimental JAK1/2 inhibitor with any one or
             more of the following:

             a. Inadequate response after being on ≥ 3 months of treatment defined by: i. Palpable
             spleen ≥ 10 cm below the left subcostal margin on physical examination at the
             screening visit OR ii. Palpable spleen ≥ 5cm below the left subcostal margin on
             physical examination at the screening visit AND active symptoms of MF at the screening
             visit defined presence of 1 symptom score of ≥ 5 or two symptom scores each of ≥ 3
             using the Screening Symptoms Form (Appendix 6) b. Intolerant to ruxolitinib and/or
             other JAK1/2 inhibitors due to any grade ≥ 3 non-hematologic AEs of or any grade ≥ 2
             AEs requiring treatment discontinuation AND palpable spleen ≥ 5cm below the left
             subcostal margin on physical examination at the screening visit.

          -  Adequate organ function as defined as:

               -  Hematologic (≤ 7 days prior to C1D1):

                    -  Total white blood cell (WBC) count ≥ 1000/mm3

                    -  Absolute neutrophil count (ANC) ≥ 500/mm3

                    -  Hemoglobin ≥ 7 g/dL

                    -  Platelet count ≥ 30,000/mm3

        For patients receiving transfusion and growth factor support, the following delays must be
        observed between the last administration and hematologic laboratory screening assessments:

        • For hematopoietic growth factor support (including erythropoietin, darbepoetin,
        granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage-colony stimulating
        factor [GM-CSF], and platelet stimulators [e.g., eltrombopag, romiplostim, or
        interleukin-11]): at least 2 weeks.

        Growth factor support, RBC and/or platelet transfusions are allowed as clinically indicated
        per institutional guidelines during the study.

          -  Hepatic (≤ 28 days prior to C1D1):

               -  Total bilirubin &lt; 1.5 × ULN except in patients with indirect hyperbilirubinemia
                  due to hemolysis or with Gilbert's syndrome where total bilirubin should be &lt; 5 ×
                  ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 × ULN.

          -  Renal (within 28 days prior to C1D1):

               -  Estimated creatinine clearance (CrCl) ≥ 20 mL/min using the Cockroft and Gault
                  formula [(140-Age) × Mass (kg)/(72 × creatinine mg/dL), multiply by 0.85 if the
                  patient is female] OR

                    -  Female patients of childbearing potential must have a negative serum
                       pregnancy test (≤ 3 days prior to C1D1).

                    -  Female patients of childbearing potential must agree to use 2 methods of
                       contraception throughout the study and for 3 months following the last dose
                       of study treatment (including 1 highly effective and 1 effective method of
                       contraception as defined in section 7.4)

                    -  Male patients must use an effective barrier method of contraception if
                       sexually active with a female of childbearing potential.

                    -  Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any
                       prior treatments including ruxolitinib or other experimental agents, unless
                       AE(s) are clinically nonsignificant and/or stable on supportive therapy.

                    -  Able to provide informed consent and willing to sign an approved consent
                       form that conforms to federal and institutional guidelines.

        Exclusion Criteria:

          -  Prior exposure to a SINE compound, including selinexor.

          -  BSA &lt; 1.4 m2 at baseline, calculated by the Dubois or Mosteller methods.

          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals ≤ 1 week prior to C1D1. Patients on prophylactic antibiotics or with a
             controlled infection ≤ 1 week prior to C1D1 are acceptable.

          -  Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including
             investigational therapies) ≤ 2 weeks.

          -  Ruxolitinib or other JAK1/2 inhibitors ≤ at least 3 days or 5 half-lives prior to
             C1D1.

          -  Major surgery ≤ 4 weeks prior to C1D1.

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.

          -  Any active gastrointestinal dysfunction interfering with the patient's ability to
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with
             absorption of study treatment.

          -  Any life-threatening illness, organ system dysfunction, or serious psychiatric,
             medical, or other conditions/situations which, in the investigator's opinion, could
             compromise a patient's ability to give informed consent, safety, or compliance with
             the protocol.

          -  Contraindication to any of the required concomitant drugs or supportive treatments.

          -  Subjects taking prohibited medications as described in Section 6.3. Following
             discontinuation of prohibited medications, a washout period is required prior to
             initiating study treatment (the duration of the washout must be as clinically
             indicated, e.g. at least five half-lives).

          -  Subjects who are breastfeeding and unwilling to stop while on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Tantravahi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priscilla Blosser, RN</last_name>
    <phone>801-213-6117</phone>
    <email>Priscilla.blosser@hci.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Blosser, RN</last_name>
      <phone>801-213-6117</phone>
      <email>Priscilla.blosser@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

